Role of serum lactic dehydrogenase, glutamic oxaloacetic transaminase, creatine phosphokinase, alkaline phospatase, serum phosphorus in the cases of bowel ischemia in acute abdomen

Soni, N.; Bhutra, Shyam; Vidyarthi, Shivaji H.; Sharma, Vivek; Singh, Amit

doi:10.18203/2349-2902.isj20172399

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical studies found that LDH is a useful biomarker for acute mesenteric ischemia, [ 55 , 56 ]. However, interpretation of the results may be difficult in COVID-19 patients, as both lactate and LDH were also found to be independent risk factors of severe forms of COVID-19 [ 57 , 58 ].…”

Section: Discussionmentioning

confidence: 99%

Acute Mesenteric Ischemia in COVID-19 Patients

Serban

Tribus

Vancea

et al. 2021

JCM

View full text Add to dashboard Cite

Acute mesenteric ischemia is a rare but extremely severe complication of SARS-CoV-2 infection. The present review aims to document the clinical, laboratory, and imaging findings, management, and outcomes of acute intestinal ischemia in COVID-19 patients. A comprehensive search was performed on PubMed and Web of Science with the terms “COVID-19” and “bowel ischemia” OR “intestinal ischemia” OR “mesenteric ischemia” OR “mesenteric thrombosis”. After duplication removal, a total of 36 articles were included, reporting data on a total of 89 patients, 63 being hospitalized at the moment of onset. Elevated D-dimers, leukocytosis, and C reactive protein (CRP) were present in most reported cases, and a contrast-enhanced CT exam confirms the vascular thromboembolism and offers important information about the bowel viability. There are distinct features of bowel ischemia in non-hospitalized vs. hospitalized COVID-19 patients, suggesting different pathological pathways. In ICU patients, the most frequently affected was the large bowel alone (56%) or in association with the small bowel (24%), with microvascular thrombosis. Surgery was necessary in 95.4% of cases. In the non-hospitalized group, the small bowel was involved in 80%, with splanchnic veins or arteries thromboembolism, and a favorable response to conservative anticoagulant therapy was reported in 38.4%. Mortality was 54.4% in the hospitalized group and 21.7% in the non-hospitalized group (p < 0.0001). Age over 60 years (p = 0.043) and the need for surgery (p = 0.019) were associated with the worst outcome. Understanding the mechanisms involved and risk factors may help adjust the thromboprophylaxis and fluid management in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Mesenteric Ischemia in COVID-19 Patients

Serban

Tribus

Vancea

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…LDH levels were found to have increased to 623 U/L in AMI patients in the COVID-19 period 16 . Serum AST values were found to be significantly higher in patients with intestinal ischemia when compared to those who did not have intestinal ischemia 29 . It was also reported that serum AST levels were increased during the COVID-19 infection due to both increased viral load and tissue hypoperfusion 30 .…”

Section: Discussionmentioning

confidence: 83%

Evaluation of the possible effects of the COVID-19 period on the clinical outcomes of acute mesenteric ischemia

TaÓkin,

Akar,

ÓstuÓner

et al. 2024

CIRUE

View full text Add to dashboard Cite

Objective:The objective of the study was to investigate the possible effects of the coronavirus disease 2019 period on the frequency and clinical course of acute mesenteric ischemia (AMI) cases. Material and methods: A total of 35 patients who were treated and followed up with a diagnosis of AMI over 44 months were included. Results: The mean age of the patients was 69 ± 12 years. Of these patients, 22 were male (63%). The most common cause of AMI in the patients was arterial embolism/thrombosis (68.6%). Thirty-three (94%) of the patients underwent surgical intervention. The duration of the pre-COVID-19 and COVID-19 periods was equal as 22 months, and 18 (51%) of the patients were admitted during the pandemic period. The mortality rate of the patients admitted during the COVID-19 period was also significantly higher than that of the patients admitted during the pre-COVID-19 period (61% and 29%) (p = 0.05). Conclusions: Although the COVID-19 period did not cause a significant increase in the number of AMI cases when compared to the pre-COVID-19 period, the mortality rate was higher in this period. It is thought that further studies are required to investigate the cause of this increased mortality rate during the pandemic period.

show abstract